Live feed06:30:00·631dPRReleasevia QuantisnowShattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling PathwayByQuantisnow·Wall Street's wire, on your screen.STTK· Shattuck Labs Inc.Health Care
